Female Specific Therapeutics

We aim to elevate women’s health and autonomy, with AH’s psychedelic medicine discovery, provider network and community engagement programmes; rooted in evidence-based, functional and personalized medicine.

Addressing female hormone-related mood disorders (FHRMD) in menopause.

Our aim is to disrupt the existing antidepressant market used to treat FHRMD ineffectively, with a low-dose, targeted, take-at-home medicine.

WITHIN FOUR YEARS, OVER ONE BILLION WOMEN WILL BE EXPERIENCING
MENOPAUSE GLOBALLY, GENERATING A POTENTIAL MARKET OF $16B.

What are female hormone-related mood disorders?

Estradiol (E2) increases the expression of 5-HT2A receptor & serotonin transporter.

PMS

Premenstrual dysphoric disorder (PMDD)

Menopause

Peri-menopause > Menopause > Post-menopause

53%

of women are willing to try psychedelics to treat depression and anxiety.

The Challenge of Menopause

Menopause is an overlooked health condition impacting a billion women globally every year, including 42 million in the US. During menopause, almost every woman suffers from these symptoms over a 3–10 year period:

Anxiety

Depression

General Malaise

Sexual Dysfunction

Current Treatment Issues

Ignored

While physical symptoms may be treated through hormonal replacement therapy, related mental health issues are neglected.

Ineffective

Existing anti-depression drugs are ineffective for mild depression.

Aphrodite is putting women’s health first. Our plan is to expand beyond women and menopause, to include other female use cases as well as men.

Our product strategy will be to develop an API (active pharmaceutical ingredient) that will enable us to enter new markets and new consumer segments with high efficacy.

Learn More